Screening for congenital toxoplasmosis: accuracy of immunoglobulin M and immunoglobulin A tests after birth

被引：53

作者：

Gilbert, Ruth E.

Thalib, Lukman

Tan, Hooi Kuan

Paul, Margaret

Wallon, Martine

Petersen, Eskild

机构：

[1] Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London WC1N 1EH, 30, Guilford Street

[2] Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London

[3] Department of Community Medicine and Behavioural Sciences, Faculty of Medicine, Kuwait University, Kuwait 13110

[4] Department and Clinic of Tropical and Parasitic Diseases, University of Medical Sciences, Poznan

[5] Service de Parasitologie, Hôpital de la Croix Rousse, Lyon

[6] Department of Infectious Diseases, Aarhus University Hospital, Skejby, DK-8200, Aarhus N

来源：

JOURNAL OF MEDICAL SCREENING | 2007年 / 14卷 / 01期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1258/096914107780154440

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objectives: To determine the accuracy of postnatal screening for toxoplasma-specific immunoglobulin (Ig) M and IgA. Setting: Ten centres in three European countries. Methods: We compared results of the first postnatal IgM or IgA test in infants with infected mothers identified by prenatal screening with the reference standard for congenital infection status of specific IgG status at one year of age. Results: In all, 170 infected and 822 uninfected infants were analysed. Overall, IgM or IgA testing detected only 52-55% of infected infants. Sensitivity was highest between one and two weeks after birth and declined thereafter. Specificity was highest from four weeks after birth. For IgM, but not IgA, sensitivity was statistically significantly lower if the mother seroconverted in the first and second trimesters of pregnancy (29% and 34%, respectively) than the third (71%). Prenatal treatment with pyrimethamine- sulphonamide did not significantly reduce IgM or IgA sensitivity. Sensitivity was lowest for the immunofluorescence (IF) IgM test (10%) and the enzyme-linked immunosorbent assay (ELISA) IgM test (29%), but similar for the immunosorbent agglutination assay (ISAGA) IgM (54%), ISAGA IgA (58%) and ELISA IgA (52%) tests. Specificity was significantly lower for the ISAGA IgA test (91%) than for the ISAGA IgM (96%), IF IgM (100%), and ELISA IgA tests (98%). Conclusions: Poor performance of IgM and IgA tests in the newborn, particularly if the mother seroconverted in early pregnancy, casts doubt on the value of neonatal screening in industrialized countries where the risk of clinical manifestations during childhood is low. More accurate diagnostic tests are needed for newborns identified by prenatal screening.

引用

页码：8 / 13

页数：6

共 40 条

[1]

Remington J.S., McLeod R., Thulliez P., Desmonts G., Toxoplasmosis In: Remington JS, Infectious Diseases of the Fetus and Newborn Infant, pp. 205-346, (2001)

[2]

Thiebaut R., Leproust S., Chene G., Gilbert R.E., The SYROCOT Study Group. Effectiveness of prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients' data, Lancet, 369, pp. 115-122, (2007)

[3]

Binquet C., Wallon M., Quantin C., Et al., Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis, Epidemiol Infect, 131, pp. 1157-1168, (2003)

[4]

Guerina N.G., Hsu H.W., Meissner H.C., Et al., Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group (see comments), N Engl J Med, 330, pp. 1858-1863, (1994)

[5]

Lebech M., Andersen O., Christensen N.C., Et al., Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment, Lancet, 353, pp. 1834-1837, (1999)

[6]

Neto E.C., Anele E., Rubim R., Et al., High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-year prospective neonatal screening study, Int J Epidemiol, 29, pp. 941-947, (2000)

[7]

Paul M., Petersen E., Pawlowski Z.S., Szczapa J., Neonatal screening for congenital toxoplasmosis in the Poznan region of Poland by analysis of Toxoplasma gondii-specific IgM antibodies eluted from filter paper blood spots, Pediatr Infect Dis J, 19, pp. 30-36, (2000)

[8]

Paul M., Petersen E., Szczapa J., Prevalence of congenital Toxoplasma gondii infection among newborns from the Poznan region of Poland: Validation of a new combined enzyme immunoassay for Toxoplasma gondii-specific immunoglobulin A and immunoglobulin M antibodies, J Clin Microbiol, 39, pp. 1912-1916, (2001)

[9]

Evengard B., Petterson K., Engman M.-L., Et al., Low incidence of toxoplasma infection during pregnancy and in newborns in Sweden, Epidemiol Infect, 127, pp. 121-127, (2001)

[10]

Petersen E., Schmidt D.R., Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis: What are the options?, Expert Rev Anti Infect Ther, 1, pp. 175-182, (2003)

← 1 2 3 4 →